Loading

Investment Toolbox to Advance TB Vaccine Development Through Joint Action

Shaun Palmer (IAVI), Maite Suarez (IAVI), Erica Lessem (SMART4TB / Johns Hopkins School of Medicine), Henry Diatmo (Stop TB Partnership Indonesia), Karen Hoehn (advocacy), Mike Frick (Treatment Action Group)
This Policy Brief was first published in https://t20ind.org

Abstract

Tuberculosis (TB), which continues to be a global pandemic, is a pressing public health, human rights, and economic concern. At least one new TB vaccine must be licensed and approved by 2025 to meet the World Health Organization’s (WHO) goal of ending TB by 2030. The G20 includes many countries with a high burden of TB and is uniquely positioned to lead TB vaccine development and delivery through joint, sustained, and scaled-up investments. This Policy Brief outlines recommendations for G20 members to act together to accelerate TB vaccine development. An “investment toolbox” is proposed, adaptable to each country’s economic and research capacities and disease burden.

Authors

Shaun Palmer (IAVI), Maite Suarez (IAVI), Erica Lessem (SMART4TB / Johns Hopkins School of Medicine), Henry Diatmo (Stop TB Partnership Indonesia), Karen Hoehn (advocacy), Mike Frick (Treatment Action Group)

Latest Policy Briefs

Register for Updates

Would you like to receive updates on the Global Solutions Initiative, upcoming events, G7 and G20-related developments and the future of multilateralism? Then subscribe here!

1 You hereby agree that the personal data provided may be used for the purpose of updates on the Global Solutions Initiative by the Global Solutions Initiative Foundation gemeinnützige GmbH. Your consent is revocable at any time (by e-mail to [email protected] or to the contact data given in the imprint). The update is sent in accordance with the privacy policy and to advertise the Global Solutions Initiative’s own products and services.